Cybin (HELP) EBITDA (2020 - 2022)

Cybin (HELP) posted quarterly EBITDA of $4.6 million for Q2 2022, up 3028.51% on a QoQ basis from $145656.7 in Q1 2021.

Cybin (HELP) EBITDA (2020 - 2022) Analysis & Trends

Cybin (HELP) has reported EBITDA for 3 consecutive years, with $4.6 million the latest figure, recorded in Q2 2022.

Quarterly EBITDA changed N/A year-over-year to $4.6 million in Q2 2022, while the trailing twelve-month figure through May 2022 was -$157.4 million (changed N/A YoY) and the FY2026 annual result came in at -$79.6 million, down 94.72% from the prior year.
EBITDA grew to $4.6 million in Q2 2022 per HELP's latest filing, from $145656.7 in the prior quarter.
Over the last five years, EBITDA for HELP reached as high as $144.2 million in Q2 2020 and fell as low as -$162.1 million in Q4 2020.
A 3-year average of -$2.6 million and a median of $145656.7 in 2021 frame the typical range for EBITDA.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBITDA (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-27.75 Mn
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	249.90 Mn
4	NuCana	279.75 Bn	279.75 Bn	-	-3.72 Mn
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	1.14 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	642.90 Mn
7	Belite Bio	62.51 Bn	62.51 Bn	-	-32.68 Mn
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	493.00 Mn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-445.22 Mn
10	Cybin	28.04 Mn	28.04 Mn	-	-

Download Data